Etoposide
What is Avopef (Etoposide)?
Approved To Treat
Top Global Experts
Related Clinical Trials
Summary: The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Summary: This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody call...
Summary: This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another...
Related Latest Advances
Brand Information
- AVOPEF can cause severe myelosuppression resulting in infection or bleeding
- Do not administer AVOPEF to patients with absolute neutrophil counts of less than 500 cells/mm
- Monitor complete blood cell counts, prior to the administration of AVOPEF and before each subsequent cycle, and at appropriate intervals during and after therapy
- Severe Myelosuppression
- Hypersensitivity and Infusion-Related Reactions
- Extravasation Resulting in Tissue Necrosis
- Secondary Leukemia
- Risk of Increased AVOPEF Toxicity with Low Serum Albumin
- Alcohol Content

- OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
- Advise pregnant women and females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider with a known or suspected pregnancy
- Advise females of reproductive potential to use effective contraception during treatment with AVOPEF and for 6 months after the last dose
- Advise males with female partners of reproductive potential to use effective contraception during treatment with AVOPEF and for 4 months after the last dose







